Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548]
Discontinued
Reference number: GID-TA10416
The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia.
For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme.
As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.